Aperio Group LLC raised its stake in Haemonetics Corporation (NYSE:HAE) by 15.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,695 shares of the medical instruments supplier’s stock after buying an additional 1,393 shares during the period. Aperio Group LLC’s holdings in Haemonetics Corporation were worth $422,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue boosted its stake in Haemonetics Corporation by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock valued at $232,000 after buying an additional 130 shares during the period. Municipal Employees Retirement System of Michigan boosted its stake in Haemonetics Corporation by 1.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,800 shares of the medical instruments supplier’s stock valued at $479,000 after buying an additional 150 shares during the period. Louisiana State Employees Retirement System boosted its stake in Haemonetics Corporation by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock valued at $845,000 after buying an additional 200 shares during the period. Envestnet Asset Management Inc. boosted its stake in Haemonetics Corporation by 0.9% in the first quarter. Envestnet Asset Management Inc. now owns 25,371 shares of the medical instruments supplier’s stock valued at $1,028,000 after buying an additional 225 shares during the period. Finally, American Century Companies Inc. boosted its stake in Haemonetics Corporation by 0.9% in the first quarter. American Century Companies Inc. now owns 45,846 shares of the medical instruments supplier’s stock valued at $1,860,000 after buying an additional 405 shares during the period.

Shares of Haemonetics Corporation (HAE) traded down 0.93% on Tuesday, hitting $41.39. The stock had a trading volume of 28,655 shares. The company has a market cap of $2.18 billion, a P/E ratio of 537.53 and a beta of 0.90. The company has a 50-day moving average of $40.94 and a 200-day moving average of $40.32. Haemonetics Corporation has a 52-week low of $32.76 and a 52-week high of $43.74.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The firm had revenue of $211 million during the quarter, compared to the consensus estimate of $211.29 million. During the same quarter last year, the firm earned $0.25 EPS. The firm’s revenue for the quarter was up .5% on a year-over-year basis. On average, equities analysts anticipate that Haemonetics Corporation will post $1.60 EPS for the current fiscal year.

WARNING: This article was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/haemonetics-corporation-hae-shares-bought-by-aperio-group-llc/1529979.html.

Several research firms have weighed in on HAE. Zacks Investment Research cut Haemonetics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th. JMP Securities upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a report on Thursday, July 13th. Jefferies Group LLC reiterated a “buy” rating and issued a $42.00 price objective on shares of Haemonetics Corporation in a report on Monday, May 8th. BidaskClub upgraded Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. Finally, TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. Haemonetics Corporation currently has an average rating of “Hold” and an average target price of $40.71.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.